Dexcom (DXCM) EPS (Basic) (2010 - 2026)

Dexcom (DXCM) has 17 years of EPS (Basic) data on file, last reported at $0.52 in Q1 2026.

• On a quarterly basis, EPS (Basic) rose 92.23% year-over-year to $0.52 in Q1 2026; TTM through Mar 2026 was $2.42, a 76.55% increase from a year earlier, with the FY2025 full-year figure at $2.14, up 46.41% from the prior year.
• EPS (Basic) for Q1 2026 stood at $0.52, down from $0.69 in the prior quarter.
• Over the last five years, EPS (Basic) for DXCM reached as high as $0.73 in Q3 2025 and fell as low as $0.13 in Q1 2023.
• Historically, EPS (Basic) has averaged $0.38 across 5 years, with a median of $0.34 in 2024.
• Across the five-year window, EPS (Basic) jumped 1820.51% in 2022 and slumped 49.78% in 2023, its largest moves.
• Year by year, EPS (Basic) stood at $0.24 in 2022, then surged by 181.65% to $0.66 in 2023, then plunged by 41.95% to $0.39 in 2024, then jumped by 77.74% to $0.69 in 2025, then decreased by 24.38% to $0.52 in 2026.
• Per Business Quant data, the three most recent EPS (Basic) figures were $0.52 in Q1 2026, $0.69 in Q4 2025, and $0.73 in Q3 2025.